Anisotropine methylbromide | 80-50-2

• 物质功能分类: 天然产物 - 生物碱
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: Anisotropine methylbromide
• 英文别名: [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide
• CAS: 80-50-2
• 化学式: C17H32BrNO2
• 分子量: 362.3
• InChiKey: QSFKGMJOKUZAJM-JXMYBXCISA-M

物化性质

• 熔点：
  329°
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 颜色/状态：
  CRYSTALS FROM ACETONE
• 气味：
  PROBABLY ODORLESS
• 味道：
  BITTER TASTE
• 稳定性/保质期：

  STABLE IN LIGHT, HEAT, & AIR.

计算性质

• 辛醇/水分配系数(LogP)：
  0.52
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

ADMET

毒理性

• 相互作用

食物会降低大鼠对溴化甲基阿尼索特品的吸收速率，且有证据表明存在一个可饱和的过程，影响这种化合物的肠道吸收。

RATE OF ABSORPTION OF ANISOTROPINE METHYL BROMIDE IS REDUCED BY FOOD IN RAT, & THERE IS EVIDENCE OF SATURABLE PROCESS, INFLUENCING INTESTINAL ABSORPTION OF THIS CMPD.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

抗胆碱能药物，如阿尼索特罗平，预计会与地高辛发生相互作用...可能会导致血清地高辛水平升高。/阿尼索特罗平/

...ANTICHOLINERGIC AGENTS, SUCH AS ANISOTROPINE...WOULD BE EXPECTED TO INTERACT WITH DIGOXIN.../MAY CAUSE INCR SERUM DIGOXIN LEVELS/. /ANISOTROPINE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

地西泮与甲溴辛托品相互作用，在减少隔离兔空肠的自发和刺激胃肠动力以及在兔结肠和狗胃袋的活体实验中显示出积极效果。

DIAZEPAM & OCTATROPINE METHYLBROMIDE INTERACTED POS IN REDUCING SPONTANEOUS & STIMULATED GI MOTILITY IN ISOLATED RABBIT JEJUNUM & IN VIVO IN RABBIT COLON & DOG GASTRIC POUCH.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

抗胆碱能药物的尿排泄可能会因尿液的碱化而延迟，使用尿液碱化剂如：含钙和/或镁的抗酸剂、碳酸酐酶抑制剂、柠檬酸盐、碳酸氢钠，从而增强抗胆碱能药物的治疗效果和/或副作用。抗胆碱能药物，抗痉挛药。

Urinary excretion of anticholinergics may be delayed by the alkalinization of the urine, /with the use of urinary alkalizers such as: calcium- and/or magnesium-containing antacids, carbonic anhydrase inhibitors, citrates, sodium bicarbonate/ thus potentiating the anticholinergics' therapeutic and/or side effects. /Anticholinergics, antispasmodics/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

...部分副作用在高剂量后出现是由于神经节阻滞。...毒性剂量...产生...抗胆碱能中毒的典型症状，并伴有神经节阻滞的附加效果，罕见情况下还会出现神经肌肉阻滞，但通常不会显著涉及中枢神经系统。/季铵化合物/

...SOME OF SIDE EFFECTS SEEN AFTER HIGH DOSES ARE DUE TO GANGLIONIC BLOCKADE. ... TOXIC DOSES...PRODUCE...USUAL MANIFESTATIONS OF ANTIMUSCARINIC POISONING WITH ADDNL EFFECTS OF GANGLIONIC & RARELY, NEUROMUSCULAR BLOCK, BUT USUALLY WITHOUT SIGNIFICANT CNS INVOLVEMENT. /QUATERNARY AMMONIUM CMPD/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

口服给药后吸收差且不稳定...穿透结膜的能力也很差，以至于...这类化合物在眼科学中价值有限。中枢作用通常不足，因为这些药物不易通过血脑屏障。...关于命运和排泄所知甚少.../季铵化合物/

...POORLY & UNRELIABLY ABSORBED AFTER ORAL ADMIN... PENETRATION OF CONJUNCTIVA IS ALSO POOR, SO THAT...CMPD ARE OF LITTLE VALUE IN OPHTHALMOLOGY. CENTRAL EFFECTS ARE GENERALLY LACKING, BECAUSE THESE AGENTS DO NOT READILY PASS BLOOD-BRAIN BARRIER. ...LITTLE...KNOWN OF FATE & EXCRETION... /QUATERNARY AMMONIUM CMPD/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

全身autoradiography的小鼠SC、口服或IP剂量的抗痉挛，[(14)C]阿尼斯特罗平甲溴显示，腹膜内剂量主要分布在排泄器官(肾、肝、唾液腺和肠)。

WHOLE-BODY AUTORADIOGRAPHY OF MICE GIVEN SC, ORAL, OR IP DOSES OF ANTISPASMODIC, [(14)C]ANISOTROPINE METHBROMIDE SHOWED THAT PARENTERAL DOSES WERE DISTRIBUTED MAINLY IN EXCRETORY ORGANS (KIDNEYS, LIVER, SALIVARY GLANDS, & INTESTINES).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

一些14C标记的阿尼索托品甲溴盐在给予小鼠后存在于胃粘膜、胰腺、输卵管、子宫和输精管中。这种阳离子不太可能轻易通过生物膜扩散，似乎不会轻易穿过血脑屏障、胎盘屏障或胃肠道上皮。

SOME (14)C /ANISOTROPINE METHBROMIDE/ WAS...PRESENT IN STOMACH MUCOSA, PANCREAS, OVIDUCTS, UTERUS, & SPERMATIC DUCTS /AFTER ADMIN TO MICE/. CATION WOULD NOT BE EXPECTED TO DIFFUSE EASILY ACROSS BIOLOGICAL MEMBRANES...DID NOT APPEAR READILY TO CROSS BLOOD-BRAIN OR PLACENTAL BARRIERS, OR GASTROINTESTINAL EPITHELIUM.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  Xn,N
• 安全说明：
  S36,S60,S61
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 危险品运输编号：
  UN 3077 9/PG 3

文献信息

• COMPOSITIONS AND METHODS FOR INCREASING REMYELINATION
  申请人：Frequency Therapeutics, Inc.

  公开号：US20190336490A1

  公开（公告）日：2019-11-07

  Provided are compositions and methods comprising a MAChR antagonist/inverse agonist/partial agonist and a histamine H3 receptor antagonist/inverse agonist/partial agonist for increasing proliferation Oligodendrocyte Progenitor Cells (OPCs) into mature, myelinating oligodendrocytes, and related methods of treating demyelination disorders.
• US7790905B2
  申请人：——

  公开号：US7790905B2

  公开（公告）日：2010-09-07
• US7927613B2
  申请人：——

  公开号：US7927613B2

  公开（公告）日：2011-04-19